Cellectis (CLLS) Enterprise Value Growth (3y) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Cellectis | 20.83 Bn | 20.62 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -37.66% |
| Dec 31, 2025 | -204.28% |
| Sep 30, 2025 | -37.05% |
| Jun 30, 2025 | -9.66% |
| Mar 31, 2025 | -141.86% |
| Dec 31, 2024 | -167.53% |
| Sep 30, 2024 | -8.47% |
| Jun 30, 2024 | -4.98% |
| Mar 31, 2024 | -227.34% |
| Dec 31, 2023 | 7.62% |
| Sep 30, 2023 | 29.53% |
| Jun 30, 2023 | 39.03% |
| Mar 31, 2023 | 35.78% |
| Dec 31, 2022 | 26.47% |
| Sep 30, 2022 | 30.07% |
| Jun 30, 2022 | 28.47% |
| Mar 31, 2022 | 65.50% |
| Dec 31, 2021 | 26.76% |
| Sep 30, 2021 | 24.55% |
| Jun 30, 2021 | 20.61% |
| Mar 31, 2021 | 26.51% |
| Dec 31, 2020 | 5.99% |
| Sep 30, 2020 | 2.39% |
| Jun 30, 2020 | -5.55% |
| Mar 31, 2020 | -3.99% |
| Dec 31, 2019 | -5.48% |
| Sep 30, 2019 | -3.17% |
| Jun 30, 2019 | 3.21% |
| Mar 31, 2019 | 1.64% |
| Dec 31, 2018 | -6.14% |
| Sep 30, 2018 | -51.70% |
| Jun 30, 2018 | -53.69% |
| Mar 31, 2018 | -29.11% |
| Dec 31, 2017 | -198.34% |